search button

Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells

  • Authors:
    • Xiaojun Ge
    • Qingjuan Chen
    • Yang Ping Wu
    • Yuchen  Zhang
    • Hongwei Xia
    • Dandan  Yuan
    • Qi  Chen
    • Weibing  Leng
    • Liang  Chen
    • Qiulin  Tang
    • Xiaohui  Pang
    • Feng Bi

  • View Affiliations

  • Published online on: July 15, 2014     https://doi.org/10.3892/or.2014.3331
  • Pages: 1401-1408
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gefitinib demonstrates excellent performance in the treatment of lung adenocarcinoma patients; yet, there was no added benefit in combination with chemotherapy as reported in a phase III clinical trial. For exploring the mechanism of the failed combination therapy in lung cancer, in the present study, four therapy assessment groups, including a control group, a chemotherapy group [paclitaxel + cisplatin (TP)], a gefitinib monotherapy group (G) and a combination group [paclitaxel + cisplatin + gefitinib (TP+G)], were established in an A549 cell line and mouse xenotransplanted tumor models. By HPLC, we found that the gefitinib concentration was significantly higher in the combination group when compared to that in the G group in the non-small cell lung cancer cell line, A549 (p<0.05). Following the treatment time extension, an increased cell growth rate was observed in the combination group, while the cellular concentration of gefitinib was not decreased. The expression levels of P-IGF-1R, P-SRC and P-ERK in the fourth combination treatment group were significantly higher than levels in the fourth G treatment and control groups (p<0.05). Following downregulating of IGF-1R in the fourth combination treatment group, drug sensitivity was recovered in vitro. In the mouse model, compared with the gefitinib monotherapy group, the combination group exhibited a smaller tumor volume, lower body weight and reduced survival rate (p<0.05). Gefitinib concentrations in the serum and tumor tissues in the combination therapy group were also decreased when compared with these concentrations in the gefitinib alone group. The present study is the first to demonstrate that the decreased gefitinib concentration in serum and tumor tissues is one of the reasons resulting in the failed combination treatment (chemotherapy + gefitinib) in vivo study. Frequent use of the combination treatment in A549 lung cancer cells induced IGF-1R activation which contributed to gefitinib resistance and gave rise to the failure of the combination therapy.
View Figures
View References

Related Articles

Journal Cover

October 2014
Volume 32 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.8
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.5
  • CiteScore Rank: Q1: #74/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.719
  • SCImago Journal Rank (SJR): 0.864
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Ge X, Chen Q, Wu YP, Zhang Y, Xia H, Yuan D, Chen Q, Leng W, Chen L, Tang Q, Tang Q, et al: Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells. Oncol Rep 32: 1401-1408, 2014.
APA
Ge, X., Chen, Q., Wu, Y.P., Zhang, Y., Xia, H., Yuan, D. ... Bi, F. (2014). Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells. Oncology Reports, 32, 1401-1408. https://doi.org/10.3892/or.2014.3331
MLA
Ge, X., Chen, Q., Wu, Y. P., Zhang, Y., Xia, H., Yuan, D., Chen, Q., Leng, W., Chen, L., Tang, Q., Pang, X., Bi, F."Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells". Oncology Reports 32.4 (2014): 1401-1408.
Chicago
Ge, X., Chen, Q., Wu, Y. P., Zhang, Y., Xia, H., Yuan, D., Chen, Q., Leng, W., Chen, L., Tang, Q., Pang, X., Bi, F."Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells". Oncology Reports 32, no. 4 (2014): 1401-1408. https://doi.org/10.3892/or.2014.3331